Phase 3 N=2,494 A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Participants Experiencing Adverse Events (AEs) — 668; 775; 776 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=201 An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Primary Myelofibrosis · Post-Polycythemia Vera · Myelofibrosis
Primary: Spleen Volume Response Rate (RR) — 35.8; 6.0 Percentage of Participants — p=<0.0001
Phase 3 N=734 Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
Age-related Macular Degeneration
Primary: Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye — 141; 73; 131; 147 Participants — p=<0.0001
Phase 3 N=1,892 Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
Sexually Transmitted Diseases · Gonorrhea · Chlamydia
Primary: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups — 684; 696 Participants
Phase 3 N=239 Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
Progressive Keratoconus
Primary: Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax — -0.3; 0.6 Diopters — p=0.0004
Phase 3 N=116 Platelet Rich Plasma in Levator Ani Muscle Trauma
Pelvic Floor Disorders
Primary: Changes of Levator Hiatal Area During Valsava — 20.64; 20.35; 22.35; 21.41 Cm2 — p=0.086
Phase 3 N=62 RESCUE and REVERSE Long-term Follow-up
Leber Hereditary Optic Neuropathy
Primary: Ocular Adverse Events (AEs) — 5; 1 eyes
Phase 3 N=332 Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
Strongyloides Stercoralis Infection
Primary: Cure Rate Against Strongyloides Stercoralis — 94.8; 99.4 percentage of participants
Phase 3 N=26 Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. — 0; -0.66 % HbA1c
Phase 3 N=526 Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved an ASAS40 (Assessment of SpondyloArthritis International Society Criteria) — 40.85; 22.94 percentage of participants — p=<0.0001
Phase 3 N=121 Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis
Neuroborreliosis, Borrelia Burgdorferi
Primary: Difference in Composite Clinical Score From Inclusion to Six Months After Ended Treatment — 6.4; 6.4 units on a scale
Phase 3 N=105 A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
Keratosis, Actinic
Primary: Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling…
Phase 3 N=69 Liraglutide in Type 1 Diabetes
Type 1 Diabetes
Primary: HbA1c (%) — 7.92; 7.48; 7.45; 7.58 Percent of Hemoglobin (%)
Phase 3 N=52 Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Nausea · Vomiting
Primary: Complete Response (CR) — 4; 11; 4 Participants
Phase 3 N=400 Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Carcinoma, Hepatocellular
Primary: Overall Survival — 8.7; 6.8 months